目的:使用先前开发的基于成像的预测模型,比较微波消融(MWA)后预测的增生性和非增生性肝细胞癌(HCC)的治疗结果,SMARS得分。
方法:这项多中心回顾性研究包括2013年8月至2020年9月期间连续635例不可切除的HCC患者进行MWA。根据SMARS评分将患者分层为预测的增殖表型和非增殖表型。在倾向评分匹配(PSM)之前和之后,比较了预测的增殖性和非增殖性HCC之间的总生存期(OS)和无复发生存期(RFS)。在肿瘤大小小于30mm和肿瘤大小30-50mm的亚组中,还比较了两组之间的OS和RFS。
结果:SMARS评分将127和508例患者分为预测的增殖性和非增殖性肝癌,分别。与之前的非增殖性肝癌(RFSp<0.001;OSp=0.166)和之后(RFSp<0.001;OSp=0.456)匹配时,预测的增殖性肝癌表现出较差的RFS,但OS相等。关于肿瘤大小小于30mm(p=0.098)和肿瘤大小30-50mm(p=0.680)的亚组,两组之间的OS相似。然而,在肿瘤大小为30-50mm的亚组中,预测的增殖性HCC的RFS比非增殖性HCC更差(p<0.001),而RFS在肿瘤大小小于30mm的亚组中没有差异(p=0.141)。
结论:预测的增殖性肝癌在MWA后的RFS比非增殖性肝癌差,尤其是肿瘤大小大于30毫米。然而,肿瘤的表型可能不会影响OS。
■在对肝细胞癌进行微波消融之前,应考虑肿瘤表型,因为它可能影响治疗结果.
结论:增殖性肝细胞癌(HCC)可以使用SMARS评分,基于成像的预测模型。SMARS预测的增殖性HCC在微波消融后与非增殖性HCC相比具有更差的无复发和相等的总生存期。在进行微波消融前应考虑肿瘤表型。
OBJECTIVE: To compare therapeutic outcomes of predicted proliferative and nonproliferative hepatocellular carcinoma (HCC) after microwave ablation (MWA) using a previously developed imaging-based predictive model, the SMARS score.
METHODS: This multicenter retrospective study included consecutive 635 patients with unresectable HCC who underwent MWA between August 2013 and September 2020. Patients were stratified into predicted proliferative and nonproliferative phenotypes according to the SMARS score. Overall survival (OS) and recurrence-free survival (RFS) were compared between the predicted proliferative and nonproliferative HCCs before and after propensity score matching (PSM). OS and RFS were also compared between the two groups in subgroups of tumor size smaller than 30 mm and tumor size 30-50 mm.
RESULTS: The SMARS score classified 127 and 508 patients into predicted proliferative and nonproliferative HCCs, respectively. The predicted proliferative HCCs exhibited worse RFS but equivalent OS when compared with nonproliferative HCCs before (p < 0.001 for RFS; p = 0.166 for OS) and after (p < 0.001 for RFS; p = 0.456 for OS) matching. Regarding subgroups of tumor size smaller than 30 mm (p = 0.098) and tumor size 30-50 mm (p = 0.680), the OSs were similar between the two groups. However, predicted proliferative HCCs had worse RFS compared to nonproliferative HCCs in the subgroup of tumor size 30-50 mm (p < 0.001), while the RFS did not differ in the subgroup of tumor size smaller than 30 mm (p = 0.141).
CONCLUSIONS: Predicted proliferative HCCs have worse RFS than nonproliferative ones after MWA, especially in tumor size larger than 30 mm. However, the phenotype of the tumor may not affect the OS.
UNASSIGNED: Before performing microwave ablation for hepatocellular carcinoma, the tumor phenotype should be considered because it may affect the therapeutic outcome.
CONCLUSIONS: Proliferative hepatocellular carcinoma (HCC) may be identified using the SMARS score, an imaging-based predictive model. SMARS predicted proliferative HCCs have worse recurrence-free and equivalent overall survival compared to nonproliferative HCC after microwave ablation. Tumor phenotype should be considered before performing microwave ablation.